. 2023 Feb 27;17(5):698–710. doi: 10.5009/gnl220311

Table 3.

Prospective Study on Neoadjuvant Chemotherapy for Pancreatic Cancer before Radical Resection

Author/trial	Year	Resectability	Treatment	No. of patients	Primary outcome	Median	HR (95% CI)	p-value
Jang et al.⁴⁸	2018	BR	CRT (54 Gy, GEM) → surgery → GEM	27	2-yr survival	40.7%	0.51 (0.27–0.93)	0.028
Jang et al.⁴⁸	2018	BR	Surgery → GEM	23	2-yr survival	26.1%	0.51 (0.27–0.93)	0.028
Unno et al. Prep-02/JSAP05⁴⁹-⁵¹	2019	R/BR-PV	GEM + S-1 → surgery → S-1	182	OS	36.7 mo	0.72 (0.55–0.94)	0.02
Unno et al. Prep-02/JSAP05⁴⁹-⁵¹	2019	R/BR-PV	Surgery → S-1	180	OS	26.6 mo	0.72 (0.55–0.94)	0.02
Versteijne et al. PREOPANC-1⁵²,⁵³	2020	R/BR	CRT (36 Gy, GEM) → surgery → GEM	119	OS	15.7 mo	0.73 (0.56–0.96)	0.025
Versteijne et al. PREOPANC-1⁵²,⁵³	2020	R/BR	Surgery → GEM	127	OS	14.3 mo	0.73 (0.56–0.96)	0.025
Takahashi et al. JASPAC05⁵⁴	2020	R/BR	CRT (54 Gy, S-1) → surgery	52	R0 (OS)	52% (30.8 mo)	-	-
Yamaguchi et al. NUPAT-01⁵⁵	2022	BR	mFOLFIRINOX → surgery	26	R0	73.1%	-	0.202
Yamaguchi et al. NUPAT-01⁵⁵	2022	BR	GEM + nab-PTX → surgery	25	R0	56.0%	-	0.202
Katz et al. A021501⁵⁶	2022	BR	mFOLFIRINOX → surgery → FOLFOX6	65	18-mo survival	66.7%	-	-
Katz et al. A021501⁵⁶	2022	BR	mFOLFIRINOX → SBRT (33-40 Gy) or HIGRT (25 Gy) → surgery → FOLFOX6	55	18-mo survival	47.3%	-	-

HR, hazard ratio; CI, confidence interval; BR, Borderline Resectable; CRT, chemoradiotherapy; GEM, gemcitabine; R, resectable; PV, portal vein; OS, overall survival; mFOLFIRINOX, modified FOLFIRINOX; nab-PTX, nab-paclitaxel; SBRT, stereotactic body radiation therapy; HIGRT, hypofractionated image-guided radiation therapy.